Reversibly Soluble Nicotinamide Cofactors

描述(申请人提供)：辅因子回收是主要的 辅因子依赖的酶催化反应的障碍。的发展。 易回收的可逆溶解形式的烟酰胺辅因子是 这项提案的重点。这一想法由辅因子修饰和 可逆性聚合物。因此，辅因子可以再次溶解。 在起始物的溶液或悬浮液中 条件。因此，这些辅因获得了永久的优势 可溶性辅因子(均相和非均相体系中的高活性) 和固定化辅因子(易于回收)。今天，没有可逆的 市面上的可溶性辅因子。这一想法的潜力在 初步研究。建议的第一阶段侧重于选择最好的 方法合成温度和pH响应性可逆的可溶性辅因子。 优化它们的合成，开发专有技术来 使用可逆性辅因子制造手性药物将是 第二阶段的目标。也没有专利可以合成 可逆溶解的辅因子或其在合成中的用途。可逆溶解 辅因子和手性化合物将向制药公司销售。在……里面 2000年，手性化合物的总市场达到40亿美元。 建议的商业应用： 可逆性辅因子是独特的，因为它们结合了可溶性辅因子和固定化辅因子的优点。目前还没有商业上可用的这种辅因子。它们将在Polium Technologies内部使用，并出售给制药公司，用于制造手性中间体。手性中间体的市场每年约为40亿美元。仅生产一种药物，中间体的销售每年就能带来数百万美元的收入。

DESCRIPTION (provided by applicant): Cofactor recovery is one of the major hurdles of cofactor-dependent enzyme-catalyzed reactions. The development of easily recoverable reversibly soluble form of nicotinamide cofactors is the focus of this proposal. The idea consists of the cofactor modification with reversibly soluble polymers. Consequently, the cofactor can be dissolved again in a solution or suspension of the starting materials at the initial conditions. Therefore, these cofactors acquire the advantages of permanently soluble cofactors (high activity both in homogeneous and heterogeneous systems) and of immobilized cofactors (easy recovery). Today, there are no reversibly soluble cofactors on the market. Potential of the idea was demonstrated during preliminary studies. Phase I of the proposal focuses on the choice of the best method to synthesize thermo- and pH responsive reversibly soluble cofactors. Optimization of their synthesis, development of the proprietary technology to manufacture chiral pharmaceuticals using reversibly soluble cofactors will be the goals of Phase II. There are no patents either on the synthesis of reversibly soluble cofactors or their use for synthesis. Reversibly soluble cofactors and chiral compounds will be marketed to pharmaceutical companies. In 2000, total market for chiral compounds reached $4 billion. PROPOSED COMMERCIAL APPLICATIONS: Reversibly soluble cofactors are unique because they combine advantages of soluble and immobilized cofactors. There are no cofactors of this kind commercially available. They will be used internally at Polium Technologies and sold to pharmaceutical companies to manufacture chiral intermediates. Market for chiral intermediates is about $4 billion per year. Sales of intermediates for a production of just one drug can bring several million annually.